TimesSquare Capital Management LLC Purchases New Holdings in NexImmune, Inc. (NASDAQ:NEXI)

TimesSquare Capital Management LLC purchased a new stake in NexImmune, Inc. (NASDAQ:NEXI) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 487,100 shares of the company’s stock, valued at approximately $9,294,000. TimesSquare Capital Management LLC owned approximately 2.14% of NexImmune at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in NexImmune in the 1st quarter valued at about $5,790,000. Victory Capital Management Inc. acquired a new stake in NexImmune in the 1st quarter valued at about $211,000. New York State Common Retirement Fund acquired a new stake in NexImmune in the 1st quarter valued at about $109,000. Finally, American International Group Inc. acquired a new stake in NexImmune in the 1st quarter valued at about $71,000. Institutional investors own 42.61% of the company’s stock.

Shares of NASDAQ NEXI opened at $17.83 on Friday. The business’s 50 day moving average price is $18.98. The firm has a market cap of $402.58 million and a P/E ratio of -0.67. NexImmune, Inc. has a 1 year low of $17.06 and a 1 year high of $28.00.

NexImmune (NASDAQ:NEXI) last posted its earnings results on Monday, May 17th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.05). Analysts predict that NexImmune, Inc. will post -4.34 earnings per share for the current year.

A number of research firms have commented on NEXI. Zacks Investment Research downgraded shares of NexImmune from a “hold” rating to a “sell” rating in a report on Thursday, June 3rd. Barclays started coverage on shares of NexImmune in a report on Tuesday, March 9th. They set an “overweight” rating and a $35.00 price target for the company. Raymond James started coverage on shares of NexImmune in a report on Wednesday, March 31st. They set an “outperform” rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald started coverage on shares of NexImmune in a report on Tuesday, March 9th. They set an “overweight” rating and a $35.00 price target for the company.

NexImmune Company Profile

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

Recommended Story: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding NEXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NexImmune, Inc. (NASDAQ:NEXI).

Institutional Ownership by Quarter for NexImmune (NASDAQ:NEXI)

Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.